INTRODUCTION
Primary acute illnesses or diseases are a major threat for hospitalisation in severe or acute hyperglycemic attacks in type 2 diabetes mellitus (T2DM) patients. [1, 2] . Thus far, none of the previous studies looked extensively at the possibility that genetic polymorphisms could be a factor influencing glycemic control.
The biggest challenge in dealing with acute and severe hyperglycemia is ensuring that patient glucose levels are at their target level without exposing patients to the risks of hyperglycemia and hypoglycemia. Failure to achieve optimum glycemic control during a severe or acute hyperglycemia phase poses a number of risks to patients.
Acute hyperglycemia was an independent predictor for increased mortality in the hospital [3] .
Nevertheless, neither a single genetic factor nor a combination of genetic factors was previously known to affect significantly glycemic control in T2DM patients with severe/acute hyperglycemia. Insulin Receptor Substrate (IRS) genes mainly Insulin Receptor Substrate 1 (IRS1) and Insulin Receptor Substrate 2 (IRS2) are the most speculated genes to influence the glycemic control based on their key roles to maintain the basic functions of cell growth, survival, and metabolism [4] . Therefore, this study aims to identify IRS 1 and IRS2 gene polymorphisms that could possibly influence the management and treatment of T2DM during severe/acute phase hyperglycemia.
EXPERIMENTAL Materials and chemical reagents
Wizard® Genomic DNA Purification Kit, PCR Master Mix, and 6x blue/orange loading dye were supplied by Promega (Madison, WI, USA). Water (molecular biology grade) was from SigmaAldrich (Irvine, UK). Ethanol, 50 bp DNA ladder, Trizma®, molecular biology grade DMSO, and PCR primers were supplied by Sigma-Aldrich (St. Louis, MO, USA). Low electroendosmosis (EEO) agarose was from Applichem (Darmstadt, Germany). Isopropanol, glacial acetic acid, sodium hydroxide, and EDTA were purchased from Ajax Pty Ltd (Auckland, New Zealand), and 10x NEBuffer solution and restriction enzymes (BstNI, HaeII) were from Promega and New England Biolabs (Hitchin, UK).
Apparatus
Centrifuge (Eppendorf, Hamburg, Germany), Water bath (Memmert, Schwabach, Germany), UV-160A spectrophotometer (Shimadzu, Kyoto, Japan), PTC-100TM thermocycler (MJ Research Inc., Watertown, MA, USA), Fluorchem FC2 gel documentation system (Alpha Innotech, Multimage™, USA), were used in this study.
Patient recruitment
This was a prospective study carried out in the medical wards in which 156 patients at National University of Malaysia (UKMMC) were recruited as earlier described [5] . For genetic study, SNP and its association with glycemic control in T2DM patients with severe/acute phase hyperglycemia were studied.
Glycemic control assessment
Glycemic control assessment was as earlier described [6] .
Genetic study
Genetic study was conducted based on methods as earlier described [5] .
Data analysis
Data collected for each patient were classified by the specific allele, genotype, and haplotype. Fisher's exact test and χ 2 tests were used for nominal data. Spearman's correlation was used for association of gene polymorphisms with glycemic control. HWE test was used as a measure of quality control for genotyping methods [7, 8] . A p-value > 0.05 indicates that the observed distribution of genotypes was consistent with the HWE assumption. This situation also proves that the results of the PCR-RFLP method are applicable. Table 1 shows the relationship between gene variants of IRS1 and IRS2. The χ 2 and Spearman's rho correlation tests showed that the relationship between the variants of these genes was not significant. Figures 1 and 2 show that there were no associations between the variants in IRS1 and IRS2 genes and glycemic control in patients with severe/acute phase hyperglycemia. 
RESULTS

Association between variants of IRS1 and IRS2 genes
Influence of IRS genes on glycemic control
DISCUSSION
This study showed that there was no significant association between polymorphisms of genes IRS1 and IRS2 in patients with T2DM with severe or acute hyperglycemia. Although both IRS1 and IRS2 genes were included in the IRS system, their signaling specificity and distribution in tissues were different [4] . This result is supported by another study that found no significant interaction between the variants of these two genes [9] . Previous studies of the IRS1 gene were focused on the sensitivity and resistance to insulin in general patients with diabetes [4, 10, 11] , while studies of the IRS2 gene polymorphisms were focused on insulin resistance, obesity, endometriosis, and polycystic ovary syndrome [2, 9] . However, none of the studies involved T2DM patients with severe/acute hyperglycemia. This study found that neither IRS1 nor IRS2 gene polymorphisms correlated with glycemic control during severe hyperglycemia or acute phase. For IRS1 gene polymorphisms, the lack of a correlation with glycemic control may be due to the polymorphism having a direct relationship with insulin resistance and not glycemic control. The IRS2 gene polymorphisms may be associated with insulin resistance, but most studies cannot prove this theory [12, 13] . However, polymorphisms in IRS1 and IRS2 genes might indirectly influence glycemic control. A study found that the Gly972Arg polymorphism in patients with T2DM causes weakness in the secretion of insulin, resulting in insulin deficiency and poor glycemic control [14] . The IRS1 gene polymorphism may predict the glycemic control of hyperglycemia during the acute phase if other factors, such as insulin resistance, were included in the analysis [15] . In other words, insulin resistance was seen as a subset of glycemic control. Thus, by studying other factors such as demographic and clinical factors that influence insulin resistance and glycemic control during severe hyperglycemia or acute phase directly and simultaneously, a clear relationship can be obtained [6] . Therefore, genetic factors alone might not be significant determinants for glycemic control in T2DM patients with severe/acute hyperglycemia. Other factors such as demographic and clinical factors may be considered in combination with genetic factors to improve glycemic control and quality of life for this group of patients.
CONCLUSION
IRS1 and IRS2 genetic factors may not be significant genetic determinants for glycemic control in T2DM patients in severe/acute phase hyperglycemia.
Limitation of the study
This study focused on a specific study population; hence, it might not be possible to extrapolate these results to other races or countries.
